Terlipressin
Also referenced as: Terlivaz
A vasopressin analogue used for a specific form of hepatorenal syndrome.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
Terlivaz is FDA-approved to improve kidney function in adults with hepatorenal syndrome with rapidly declining kidney function.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A vasopressin analogue used for a specific form of hepatorenal syndrome.
Terlivaz is FDA-approved to improve kidney function in adults with hepatorenal syndrome with rapidly declining kidney function.
Very advanced renal dysfunction lowers the chance of response. Critical-care use cannot be framed as liver or kidney wellness enhancement.
Why It's Being Studied
- Hepatorenal syndrome
- Vascular and renal physiology
Mechanism of Action
Predominantly V1-mediated vasoconstriction changes circulatory dynamics to improve kidney function in the studied disease context.
Predominantly V1-mediated vasoconstriction changes circulatory dynamics to improve kidney function in the studied disease context. Very advanced renal dysfunction lowers the chance of response. Critical-care use cannot be framed as liver or kidney wellness enhancement.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Hepatorenal syndrome
- Vascular and renal physiology
- Intravenous approved medicine
Evidence Summary
CONFIRM demonstrated increased verified hepatorenal-syndrome reversal, not an established survival benefit.
Higher tiers carry more weight. Filled tiers have evidence for Terlipressin; tap to read it.
- CONFIRM demonstrated increased verified hepatorenal-syndrome reversal, not an established survival benefit.
1 cited sources.
- Prescribing label1
Human clinical evidence
- CONFIRM demonstrated increased verified hepatorenal-syndrome reversal, not an established survival benefit.
Reported Adverse Events in Research
- The boxed warning covers serious or fatal respiratory failure; ischemia is another important risk.
Limitations of Current Evidence
- Very advanced renal dysfunction lowers the chance of response. Critical-care use cannot be framed as liver or kidney wellness enhancement.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Terlipressin | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Terlipressin — prescribing label